Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.32
(-5.88%)
HKD 0.32
(-5.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.09 Billion HKD | -70.13% |
| 2022 | 7.01 Billion HKD | -7.69% |
| 2021 | 7.59 Billion HKD | -4.61% |
| 2020 | 7.96 Billion HKD | 3.03% |
| 2019 | 7.73 Billion HKD | 123.76% |
| 2018 | 3.45 Billion HKD | -5.52% |
| 2017 | 3.65 Billion HKD | 2.33% |
| 2016 | 3.57 Billion HKD | 10.37% |
| 2015 | 3.23 Billion HKD | 14.64% |
| 2014 | 2.82 Billion HKD | 20.22% |
| 2013 | 2.34 Billion HKD | 14.46% |
| 2012 | 2.05 Billion HKD | 26.01% |
| 2011 | 1.62 Billion HKD | -9.58% |
| 2010 | 1.8 Billion HKD | 45.62% |
| 2009 | 1.23 Billion HKD | 64.24% |
| 2008 | 753.12 Million HKD | -37.44% |
| 2007 | 1.2 Billion HKD | 51.81% |
| 2006 | 792.91 Million HKD | -5.15% |
| 2005 | 835.98 Million HKD | 0.99% |
| 2004 | 827.81 Million HKD | 76.37% |
| 2003 | 469.35 Million HKD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 6.58 Billion HKD | 0.0% |
| 2023 FY | 2.09 Billion HKD | -70.13% |
| 2023 Q4 | 2.09 Billion HKD | 0.0% |
| 2022 Q2 | 6.91 Billion HKD | 0.0% |
| 2022 FY | 7.01 Billion HKD | -7.69% |
| 2022 Q4 | 7.01 Billion HKD | 0.0% |
| 2021 Q4 | 7.59 Billion HKD | 0.0% |
| 2021 Q2 | 8.03 Billion HKD | 0.0% |
| 2021 FY | 7.59 Billion HKD | -4.61% |
| 2020 Q4 | 7.96 Billion HKD | 0.0% |
| 2020 FY | 7.96 Billion HKD | 3.03% |
| 2020 Q2 | 7.93 Billion HKD | 0.0% |
| 2019 FY | 7.73 Billion HKD | 123.76% |
| 2019 Q2 | 3.65 Billion HKD | 0.0% |
| 2019 Q4 | 7.73 Billion HKD | 0.0% |
| 2018 Q4 | 3.45 Billion HKD | 0.0% |
| 2018 Q2 | 3.59 Billion HKD | 0.0% |
| 2018 FY | 3.45 Billion HKD | -5.52% |
| 2017 FY | 3.65 Billion HKD | 2.33% |
| 2017 Q2 | 3.52 Billion HKD | 0.0% |
| 2017 Q4 | 3.65 Billion HKD | 0.0% |
| 2016 Q4 | 3.57 Billion HKD | 0.0% |
| 2016 Q2 | 3.64 Billion HKD | 0.0% |
| 2016 FY | 3.57 Billion HKD | 10.37% |
| 2015 Q4 | 3.23 Billion HKD | 0.0% |
| 2015 Q2 | 3.1 Billion HKD | 0.0% |
| 2015 FY | 3.23 Billion HKD | 14.64% |
| 2014 Q3 | 2.82 Billion HKD | 12.15% |
| 2014 FY | 2.82 Billion HKD | 20.22% |
| 2014 Q1 | 2.51 Billion HKD | 7.19% |
| 2014 Q4 | 2.82 Billion HKD | 0.0% |
| 2014 Q2 | 2.51 Billion HKD | 0.0% |
| 2013 Q1 | 2.2 Billion HKD | 7.62% |
| 2013 Q4 | 2.34 Billion HKD | 0.0% |
| 2013 FY | 2.34 Billion HKD | 14.46% |
| 2013 Q3 | 2.34 Billion HKD | 6.35% |
| 2013 Q2 | 2.2 Billion HKD | 0.0% |
| 2012 Q1 | 1.68 Billion HKD | 3.2% |
| 2012 Q4 | 2.05 Billion HKD | 0.0% |
| 2012 Q3 | 2.05 Billion HKD | 22.1% |
| 2012 FY | 2.05 Billion HKD | 26.01% |
| 2012 Q2 | 1.68 Billion HKD | 0.0% |
| 2011 Q4 | 1.62 Billion HKD | 0.0% |
| 2011 FY | 1.62 Billion HKD | -9.58% |
| 2011 Q2 | 1.72 Billion HKD | 0.0% |
| 2010 FY | 1.8 Billion HKD | 45.62% |
| 2010 Q2 | 1.36 Billion HKD | 0.0% |
| 2010 Q4 | 1.8 Billion HKD | 0.0% |
| 2009 Q4 | 1.23 Billion HKD | 0.0% |
| 2009 FY | 1.23 Billion HKD | 64.24% |
| 2008 FY | 753.12 Million HKD | -37.44% |
| 2007 FY | 1.2 Billion HKD | 51.81% |
| 2006 FY | 792.91 Million HKD | -5.15% |
| 2005 FY | 835.98 Million HKD | 0.99% |
| 2004 FY | 827.81 Million HKD | 76.37% |
| 2003 FY | 469.35 Million HKD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | -130.875% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 90.695% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | -62.766% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -338.2% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 27.522% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | 25.904% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | -21.291% |
| PuraPharm Corporation Limited | 843.96 Million HKD | -148.247% |
| SSY Group Limited | 11.96 Billion HKD | 82.492% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | -50.869% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 39.914% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 99.229% |